Thyroid DysfunctionNCT07157267
Evaluation of Thyroid Function, Lipid Profile, and Uric Acid Levels in Hemodialysis Patients
An observational study of Thyroid Dysfunction and Hemodialysis, run by Assiut University.
Trial summary
This observational study evaluates the prevalence and relationships of thyroid dysfunction, lipid abnormalities, and elevated uric acid levels in adult patients undergoing maintenance hemodialysis at Assiut University Hospital. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Thyroid Dysfunction, Hemodialysis, Elevated Uric Acid
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 Jul 2026to 30 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: the study population consists of adult patients aged 18 years or older, undergoing regular hemodialysis treatment at Assiut University Hospital for a minimum of three months, excluding those with pre-existing thyroid disorders or on relevant medications.
Who may be able to join
- Adults ≥18 years
- On regular hemodialysis for ≥3 months
Who cannot join
- On lipid-lowering or uric acid-lowering medications
- Acute infections or hospitalizations in the past month
About this study
Official title: Evaluation of Thyroid Function, Lipid Profile, and Uric Acid Levels in Patients Undergoing Hemodialysis Prevalence in Assiut University Hospital
This observational study evaluates the prevalence and relationships of thyroid dysfunction, lipid abnormalities, and elevated uric acid levels in adult patients undergoing maintenance hemodialysis at Assiut University Hospital.
Read the detailed description
Chronic kidney disease (CKD) patients on maintenance hemodialysis frequently experience metabolic disturbances including thyroid hormone imbalances, dyslipidemia, and hyperuricemia, which heighten cardiovascular risk. This prospective cross-sectional study aims to investigate the prevalence and interrelations of thyroid function abnormalities (measured via serum TSH, Free T3, Free T4), lipid disorders (total cholesterol, HDL-C, LDL-C, triglycerides), and serum uric acid levels in a cohort of 100 adult patients undergoing regular hemodialysis for at least three months at Assiut University Hospital. Data will be collected through questionnaires, clinical exams, ultrasound thyroid scanning, and detailed laboratory and dialysis records review. The study also examines correlations between these biochemical parameters and patients' demographic and clinical characteristics, such as age, gender, smoking status, dialysis duration/frequency, and comorbidities like diabetes mellitus and hypertension. Statistical analyses using SPSS will identify the prevalence of metabolic alterations and their clinical implications in this vulnerable population.
- Conditions
- Thyroid Dysfunction, Hemodialysis, Elevated Uric Acid
- Keywords
- hemodialysis, elevated uric acid, Thyroid Function Status
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| The study population consists of adult patients aged 18 years or older, undergoing regular hemodialy | The study involves 100 adult patients (≥18 years) who are on maintenance hemodialysis for three months or more. Patients with any known thyroid disorder prior to starting dialysis, those receiving lipid-lowering agents or uric acid-lowering medications, and those recently hospitalized or with acute infections in the last month are excluded. The population reflects a typical CKD hemodialysis demographic seen at Assiut University Hospital and includes diverse participants with varying ages, genders, smoking histories, and comorbid conditions such as diabetes mellitus and hypertension. Clinical and demographic data will be systematically gathered, including dialysis durations and adequacy, to provide comprehensive insights into the interplay of thyroid, lipid, and uric acid metabolism in these patients. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Thyroid Function Status
Assessment of the prevalence and types of thyroid dysfunction in hemodialysis patients
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Sep 2025
- Study start1 Jul 2026 (estimated)
- Primary completion30 Oct 2027 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Thyroid DysfunctionStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nermen Maher, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07157267
- Sponsor's protocol ID
- Hemodialysis Patients
- Status last verified
- Aug 2025
- First submitted
- 28 Aug 2025
- Last updated
- 5 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Liu WC, Tomino Y, Lu KC. Impacts of uric acid on chronic kidney disease progression: a review. J Adv Res. 2017;8(5):449-56.
Study at a glance
From the registry record, last updated by the sponsor on 5 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Thyroid Function, Lipid Profile, and Uric Acid Levels in Patients Undergoing Hemodialysis Prevalence in Assiut University Hospital
- ClinicalTrials.gov ID
- NCT07157267
- Acronym / sponsor ID
- Hemodialysis Patients
- Conditions
- Thyroid Dysfunction, Hemodialysis, Elevated Uric Acid
- Keywords
- hemodialysis, elevated uric acid, Thyroid Function Status
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jul 2026 (estimated)
- Primary completion
- 30 Oct 2027 (estimated)
- Study completion
- 30 Dec 2027 (estimated)
- First posted
- 5 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study evaluates the prevalence and relationships of thyroid dysfunction, lipid abnormalities, and elevated uric acid levels in adult patients undergoing maintenance hemodialysis at Assiut University Hospital.
Detailed description
Chronic kidney disease (CKD) patients on maintenance hemodialysis frequently experience metabolic disturbances including thyroid hormone imbalances, dyslipidemia, and hyperuricemia, which heighten cardiovascular risk. This prospective cross-sectional study aims to investigate the prevalence and interrelations of thyroid function abnormalities (measured via serum TSH, Free T3, Free T4), lipid disorders (total cholesterol, HDL-C, LDL-C, triglycerides), and serum uric acid levels in a cohort of 100 adult patients undergoing regular hemodialysis for at least three months at Assiut University Hospital. Data will be collected through questionnaires, clinical exams, ultrasound thyroid scanning, and detailed laboratory and dialysis records review. The study also examines correlations between these biochemical parameters and patients' demographic and clinical characteristics, such as age, gender, smoking status, dialysis duration/frequency, and comorbidities like diabetes mellitus and hypertension. Statistical analyses using SPSS will identify the prevalence of metabolic alterations and their clinical implications in this vulnerable population.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| The study population consists of adult patients aged 18 years or older, undergoing regular hemodialy | – | –The study involves 100 adult patients (≥18 years) who are on maintenance hemodialysis for three months or more. Patients with any known thyroid disorder prior to starting dialysis, those receiving lipid-lowering agents or uric acid-lowering medications, and those recently hospitalized or with acute infections in the last month are excluded. The population reflects a typical CKD hemodialysis demographic seen at Assiut University Hospital and includes diverse participants with varying ages, genders, smoking histories, and comorbid conditions such as diabetes mellitus and hypertension. Clinical and demographic data will be systematically gathered, including dialysis durations and adequacy, to provide comprehensive insights into the interplay of thyroid, lipid, and uric acid metabolism in these patients. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- the study population consists of adult patients aged 18 years or older, undergoing regular hemodialysis treatment at Assiut University Hospital for a minimum of three months, excluding those with pre-existing thyroid disorders or on relevant medications.
Key inclusion criteria (2 listed)
- Adults ≥18 years
- On regular hemodialysis for ≥3 months
Key exclusion criteria (2 listed)
- On lipid-lowering or uric acid-lowering medications
- Acute infections or hospitalizations in the past month
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Thyroid Function Status
Time frame: baseline
Assessment of the prevalence and types of thyroid dysfunction in hemodialysis patients
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Sep 2025.
- BackgroundLiu WC, Tomino Y, Lu KC. Impacts of uric acid on chronic kidney disease progression: a review. J Adv Res. 2017;8(5):449-56.
Related trials for Thyroid Dysfunction
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruitingObservational study
Study of Thyroid Dysfunction in Immune Thrombocytopenic Purpura Patients
Thyroid Dysfunction, Immune Thrombocytopenic Purpura
RecruitingPhase 2
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Metabolic Dysfunction-associated Steatohepatitis
RecruitingObservational study
Postoperative Hypocalcemia After Thyroidectomy
Thyroid Nodule, Thyroid Dysfunction
Not yet recruitingObservational study
Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Thyroid Dysfunction and Hemodialysis, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Thyroid Function Status (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07157267, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2025.